TeraRecon, Inc., (TeraRecon), a diagnostic imaging company, has appointed Robert Taylor, the serving president and chief operating officer was appointed president and chief executive officer on April 1, 2009. The board has also appointed company founder and serving chief executive officer as chairman and chief technology officer on April 1, 2009.
The company also elected TeraRecon Founder Motoaki Saito, Robert James Taylor, Fumio Urano, Shigeyuki Watanabe and Matthew James Ostrander as new board members.
Motoaki Saito said “It is my greatest pleasure as a Founder and Chairman of the company to appoint Robert Taylor as President and CEO with the unanimous consent of the Board of Directors. I have prepared for this transition for several years, and have finally come to this important point, after 12 years service as CEO since the company was founded. Robert has already demonstrated his talent, passion and capability for many years, and he has served as president for the past 14 months. It is natural for him to now become the new leader of TeraRecon, to pursue the next decade of growth. Now, I am looking forward to resuming my original role of visionary, to imagine new possibilities and to create each new technology platform to bring the vision to reality, this time as CTO. To date, we have been working so hard to strengthen our current Aquarius iNtuition platform, and from now, I will to lead further engineering excellence for iNtuition, as well as the next great innovation which will follow.”
Robert Taylor said “Today’s environment, while challenging in many aspects, represents a great opportunity for TeraRecon. Our company’s mission has long been to improve the quality and effectiveness of care through the application of the most advanced technology, while reducing its cost. Today more than ever, we see that this goal is well-aligned with the newly stated goals of the U.S. administration, and we believe the same trend will continue to develop in our other key markets around the world, especially including Japan and Europe. I am confident that with the strong support our shareholders have demonstrated in the election of a very capable, experienced and committed Board of Directors, TeraRecon will be able to go from strength to strength in the coming months and years, as we continue to contribute to a new global standard of care, with world-leading innovation in the most advanced healthcare information technology. Motoaki and the Board have stated a strong commitment to the company’s vision and given clear direction regarding the path forward, and I am at once honored and challenged to be appointed at TeraRecon’s chief executive for this next phase of the company’s growth, a challenge that I welcome and embrace, on behalf of the company’s shareholders, employees, customers and all the patients in their care.”